Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Trilipix (fenofibric acid) Delayed Release Capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2012

 

Summary View

5 WARNINGS AND PRECAUTIONS

5.2 Skeletal Muscle
  • Cases of myopathy, including rhabdomyolysis.....
5.11 Paradoxical Decreases in HDL Cholesterol Levels
  • paradoxical decreases in HDL-C in patients taking fenofibrates
  • cases of myopathy, including rhabdomyolysis, have been reported in patients taking fenofibrates co-administered with colchicine

6 ADVERSE REACTIONS

6.2 Postmarketing Experience
  • paradoxical decreases in HDL-C in patients taking fenofibrates
  • cases of myopathy, including rhabdomyolysis, have been reported in patients taking fenofibrates co-administered with colchicine
-
-